Blockchain Registration Transaction Record
SignaBlok to Present Positive Preclinical Data on TREM-1 Inhibitor at 2025 AACR Annual Meeting
SignaBlok, Inc. to unveil groundbreaking preclinical data on macrophage-restricted TREM-1 inhibitor at 2025 AACR Annual Meeting. Exciting advancements in pancreatic cancer treatment with potential implications for other hard-to-treat tumors. Learn more about SignaBlok's innovative approach to inflammation-associated diseases.

This news matters as SignaBlok's innovative approach could lead to improved treatments for pancreatic cancer and other solid tumors. The development of new therapies targeting inflammation-associated diseases could significantly impact patient outcomes and survival rates.
Blockchain | Details |
---|---|
Contract Address | 0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71 |
Transaction ID | 0xab9ba0a4ac2a884b2d6afc7551409aa9fdd81a3036bee484c7e81544bb1f7b05 |
Account | 0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20 |
Chain | polygon-main |
NewsRamp Digital Fingerprint | zealZM8w-efee2e179c4f088b82874aa091f06a01 |